Vanguard Personalized Indexing Management
VRTX icon

Vanguard Personalized Indexing Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.4M Buy
43,151
+1,528
+4% +$677K 0.18% 78
2026
Q1 		$18.6M Buy
41,623
+2,458
+6% +$1.15M 0.18% 83
2025
Q4 		$17.8M Buy
39,165
+2,165
+6% +$933K 0.17% 90
2025
Q3 		$14.5M Sell
37,000
-1,491
-4% -$623K 0.15% 107
2025
Q2 		$17.1M Buy
38,491
+2,729
+8% +$1.26M 0.19% 84
2025
Q1 		$17.3M Buy
35,762
+4,584
+15% +$2.14M 0.26% 63
2024
Q4 		$12.6M Sell
31,178
-619
-2% -$287K 0.19% 81
2024
Q3 		$14.8M Buy
31,797
+2,340
+8% +$1.12M 0.24% 66
2024
Q2 		$13.7M Buy
29,457
+4,470
+18% +$1.94M 0.26% 57
2024
Q1 		$10.4M Buy
24,987
+909
+4% +$384K 0.22% 72
2023
Q4 		$9.8M Sell
24,078
-1,677
-7% -$620K 0.25% 61
2023
Q3 		$8.96M Buy
25,755
+1,495
+6% +$523K 0.27% 52
2023
Q2 		$8.54M Buy
24,260
+1,884
+8% +$635K 0.26% 55
2023
Q1 		$7.05M Buy
22,376
+1,681
+8% +$504K 0.24% 69
2022
Q4 		$5.98M Buy
20,695
+531
+3% +$162K 0.25% 65
2022
Q3 		$5.84M Buy
20,164
+1,450
+8% +$417K 0.26% 63
2022
Q2 		$5.27M Buy
18,714
+4,809
+35% +$1.29M 0.24% 70
2022
Q1 		$3.63M Buy
13,905
+3,410
+32% +$809K 0.18% 93
2021
Q4 		$2.31M Buy
10,495
+5,739
+121% +$1.12M 0.14% 134
2021
Q3 		$863K Buy
4,756
+2,235
+89% +$436K 0.08% 269
2021
Q2 		$508K Sell
2,521
-1,749
-41% -$366K 0.05% 471
2021
Q1 		$918K Buy
4,270
+1,216
+40% +$267K 0.14% 164
2020
Q4 		$722K Sell
3,054
-50
-2% -$11.5K 0.16% 146
2020
Q3 		$845K Buy
3,104
+1,416
+84% +$391K 0.24% 89
2020
Q2 		$490K Buy
1,688
+471
+39% +$128K 0.22% 110
2020
Q1 		$290K Buy
+1,217
New +$279K 0.17% 166

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Personalized Indexing Management's VRTX Position: Q2 2026 in Review

Vanguard Personalized Indexing Management increased its Vertex Pharmaceuticals (VRTX) stake by 3.7% in Q2 2026, buying an estimated $677K and bringing the position to 43,151 shares worth $21.4M. The position accounts for 0.18% of the portfolio, ranked #78.

Vanguard Personalized Indexing Management first reported a position in VRTX in Q1 2020 and has held it in 26 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Vanguard Personalized Indexing Management held 43,151 shares of Vertex Pharmaceuticals worth $21.4M as of Q2 2026.
  • Vanguard Personalized Indexing Management bought 1,528 Vertex Pharmaceuticals shares in Q2 2026, an estimated $677K.
  • Vertex Pharmaceuticals made up 0.18% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #78 holding.
  • Vanguard Personalized Indexing Management first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.